Immunoglobulin Market Size, Share & Industry Analysis, By Route of Administration (Intravenous and Subcutaneous), By Indication (Primary Immunodeficiency, Secondary Immunodeficiency, Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barré Syndrome, Immune Thrombocytopenic Purpura, Multifocal Motor Neuropathy, and Others), By Form (Liquid and Lyophilized), By End-user (Hospitals, Clinics, and Homecare), and Regional Forecast, 2026-2034

ATTRIBUTE

DETAILS

Study Period

2021-2034

Base Year

2025

Estimated Year

2026

Forecast Period

2026-2034

Historical Period

2021-2024

Growth Rate

CAGR of 9.84% from 2026-2034

Unit

Value (USD billion)

Segmentation

By Route of Administration

• Intravenous
• Subcutaneous

By Indication

• Primary Immunodeficiency (PI)
• Secondary Immunodeficiency (SID)
• Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
• Guillain Barré Syndrome
• Immune Thrombocytopenic Purpura (ITP)
• Multifocal Motor Neuropathy (MMN)
• Others

By Form

• Liquid
• Lyophilized

By End-user

• Hospitals
• Clinics
• Homecare

By Geography

• North America (By Route of Administration, By Indication, By Form, By End-user, and By Country)
  • U.S.
  • Canada
• Europe (By Route of Administration, By Indication, By Form, By End-user, and By Country/Sub-region)
  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Route of Administration, Bu Indication, By Form, By End-user, and By Country/Sub-region)
  • China
  • Japan
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Route of Administration, By Indication, By Form, By End-user, and By Country/Sub-region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Route of Administration, Bu Indication, By Form, By End-user, and By Country/Sub-region)
  • GCC
  • South Africa
  • Rest of Middle East & Africa